Features of PTEN, PAX-2 and PAX-8 expression in endometrial hyperplastic processes and endometrioid adenocarcinomas of the uterine body

Authors

DOI:

https://doi.org/10.14739/2310-1237.2026.1.356262

Keywords:

atypical endometrial hyperplasia, endometrial hyperplasia, endometrioid endometrial adenocarcinoma, PTEN, PAX-2, PAX-8

Abstract

The clinical diagnosis of atypical uterine bleeding requires differentiation of the histological diagnosis between hyperplastic processes with and without atypia and highly differentiated (grade 1) endometrial adenocarcinomas, taking into account the further treatment tactics of patients. The lack of a common picture during the study of the material after endometrial scraping necessitates the improvement of histological and immunohistochemical criteria for verification of the corresponding diagnoses.

Aim of the study. To investigate the characteristics of the expression of the 3-marker panel in hyperplastic processes of the endometrium and highly differentiated endometrioid adenocarcinomas; to determine the diagnostic sensitivity and specificity of the 3-marker panel in endometrial glandular hyperplasia with and without atypia and endometrioid adenocarcinomas (EA) grade 1 of the endometrium using the latest international classification data and taking into account the diagnostic search capabilities of the healthcare sector of Ukraine.

Materials and methods. A retrospective analysis of 60 cases of postoperative material and excision of women for the period from 2021 to 2023 with a histological diagnosis of atypical and atypical glandular hyperplasia of the endometrium and highly differentiated (grade 1) EA included an assessment of morphological, histological, immunohistochemical characteristics with subsequent statistical processing of the results obtained.

Results. In the studied sample (n = 60), a statistically significant relationship was established between the frequency of PTEN and PAX-2 expression with process atypia (atypical hyperplasia → atypical hyperplasia → G1 adenocarcinoma) according to the Cochran-Armitage test (PTEN: Z = -3.95; p < 0.001; PAX-2: Z = -4.64; p < 0.001), which was confirmed by the χ2-test (PTEN: p < 0.001; Cramer V = 0.54; PAX-2: p < 0.001; Cramer V = 0.60) and Spearman correlation (PTEN: ρ = -0.510; p < 0.001; PAX-2: ρ = -0.599; p < 0.001). For PAX-8, no intergroup differences were found (p > 0.38 for each of the three above-mentioned tests), the expression remained consistently high in all groups. Therefore, the loss of PTEN and PAX-2 expression was associated with a more malignant process in this cohort, while PAX-8 did not demonstrate discriminatory ability between the considered groups.

Conclusions. The feasibility of using the PTEN and PAX-2 panel in endometrial hyperplastic processes as a prognostic was argued.

Author Biography

P. V. Savchenko, Dnipro State Medical University

MD, Assistant of the Department of Pathological Anatomy, Forensic Medicine and Pathological Physiology

References

  1. Achanna KS, Nanda J. Evaluation and management of abnormal uterine bleeding. Med J Malaysia. 2022;77(3):374-83.
  2. Chou AJ, Bing RS, Ding DC. Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer. Diagnostics (Basel). 2024;14(22):2471. doi: https://doi.org/10.3390/diagnostics14222471
    | |
  3. Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia: ACOG Clinical Consensus No. 5. Obstet Gynecol. 2023;142(3):735-44. doi: https://doi.org/10.1097/AOG.0000000000005297
    | |
  4. Nees LK, Heublein S, Steinmacher S, Juhasz-Böss I, Brucker S, Tempfer CB, et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022;306(2):407-21. doi: https://doi.org/10.1007/s00404-021-06380-5
    | |
  5. Singh G, Cue L, Puckett Y. Endometrial Hyperplasia. [Updated 2024 Apr 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560693/
  6. Fletcher CD. Diagnostic histopathology of tumors. 4th ed. Philadelphia: Elsevier; 2013.
  7. Kurrman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of tumors of female reproductive organs. Lyon: IARC; 2014.
  8. Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383-94. doi: https://doi.org/10.1002/ijgo.14923
    | |
  9. Aguilar M, Chen H, Sahoo SS, Zheng W, Grubman J, SoRelle JA, et al. β-catenin, Pax2, and Pten Panel Identifies Precancers Among Histologically Subdiagnostic Endometrial Lesions. Am J Surg Pathol. 2023;47(5):618-29. doi: https://doi.org/10.1097/PAS.0000000000002034
    | |
  10. Lucas E, Niu S, Aguilar M, Molberg K, Carrick K, Rivera-Colon G, et al. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps. Am J Surg Pathol. 2023;47(9):1019-26. doi: https://doi.org/10.1097/PAS.0000000000002076
    | |
  11. Niu S, Molberg K, Chen J, Conrad L, Lucas E, Chen H. Expression Characteristics of 3-Marker Panel (PAX2, PTEN, and β-Catenin) in Benign Interval and Secretory Endometrium and Secretory Endometrial Precancer. Cancers (Basel). 2025;17(9):1495. doi: https://doi.org/10.3390/cancers17091495
    | |
  12. Wyvekens N, Mutter GL, Nucci MR, Kolin DL, Parra-Herran C. Lesions sub-diagnostic of endometrioid intra-epithelial neoplasia/atypical hyperplasia: value of morphology and immunohistochemistry in predicting neoplastic outcome. Histopathology. 2024;85(4):579-89. doi: https://doi.org/10.1111/his.15215
    | |
  13. Aguilar M, Chen H, Rivera-Colon G, Niu S, Carrick K, Gwin K, et al. Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry. Am J Surg Pathol. 2022;46(3):404-14. doi: https://doi.org/10.1097/PAS.0000000000001810
    | |
  14. Uccella S, Zorzato PC, Dababou S, Bosco M, Torella M, Braga A, et al. Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. Medicina (Kaunas). 2022;58(9):1256. doi: https://doi.org/10.3390/medicina58091256
    | |

Downloads

Additional Files

Published

2026-04-30

How to Cite

1.
Savchenko PV. Features of PTEN, PAX-2 and PAX-8 expression in endometrial hyperplastic processes and endometrioid adenocarcinomas of the uterine body. Pathologia [Internet]. 2026Apr.30 [cited 2026May16];23(1):29-35. Available from: https://pat.zsmu.edu.ua/article/view/356262

Issue

Vol. 23 No. 1 (2026)

Section

Original research

License

Copyright (c) 2026 P. V. Savchenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons